未知生产厂商
TRC105 is a first-in-class human chimeric monoclonal antibody that inhibits tumor growth by binding to CD105 (endoglin), a receptor over-expressed on proliferating endothelium that is required for angiogenesis (growth of new blood vessels). TRC105 has shown activity, as monotherapy or when combined with chemotherapy, in pre-clinical studies of breast and colorectal cancer. Pre-clinical data also indicate CD105 expression is increased following treatment of human cancer with anti-VEGF therapy. The target of TRC105 shares many features with the VEGF receptor. Most importantly, both the VEGF and CD105 receptors are essential for angiogenesis, in that deletion of either receptor prevents blood vessel formation in utero. [Traecon Pharmaceuticals Press Release]
Investigated for use/treatment in solid tumors.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
